Study for Subjects With Chronic Kidney Disease(CKD) Not Receiving Dialysis
Status:
Completed
Trial end date:
2005-03-01
Target enrollment:
Participant gender:
Summary
The proposed study is designed to test a novel dosing paradigm that would facilitate the
treatment of anemia in CKD patients not on dialysis. Anemic patients who are not currently
receiving ESA therapy will be dosed with darbepoetin alfa Q2W for 18 weeks.